Leqembi And Skyclarys Expected To Drive Biogen's Future Growth: Analysts

Biogen's Q4 EPS and revenue topped estimates, but analysts cite Medicare changes and MS declines as headwinds. Leqembi and Skyclarys remain key growth drivers. Latest Ratings for BIIB DateFirmActionFromTo Mar 2022StifelDowngradesBuyHold Mar 2022RBC CapitalUpgradesSector PerformOutperform Feb 2022Canaccord GenuityMaintainsBuy View More Analyst Ratings for BIIB View the Latest